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Abstract 
Bradykinin (BK) is a nonapeptide involved in several pathophysiological conditions including among 
others, septic and haemorrhagic shock, anaphylaxis, arthritis, rhinitis, asthma, inflammatory bowel disease. 
Accordingly, BK antagonists have long been sought after for therapeutic intervention. Action of BK is mediated 
through two different G-protein coupled receptors known as B1 and B2. Although there are several B1 
antagonists reported in literature, their pharmacological profile is not yet optimal so that new molecules need to 
be discovered. In the present work we have constructed an atomistic model of the B1 receptor and docked 
diverse available non-peptide antagonists in order to get a deeper insight into the structure-activity relationships 
involving binding to this receptor. The model was constructed by homology modelling using the chemokine CXC4 
and bovine rhodopsin receptors as template. The model was further refined using molecular dynamics for 600 ns 
with the protein embedded in a POPC bilayer. From the refinement process we obtained an average structure 
that was used for docking studies using the Glide software. Antagonists selected for the docking studies include 
Compound 11, Compound 12, Chroman28, SSR240612, NPV-SAA164 and PS020990. The results of the 
docking study underline the role of specific receptor residues in ligand binding. The results of this study permitted 
to define a pharmacophore that describes the stereochemical requirements of antagonist binding, and can be 
used for the discovery of new compounds. 
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Introduction 
Bradykinin (BK) is a nonapeptide with sequence Arg1-Pro2-Pro3-Gly4-Phe5-Ser6-Pro7-Phe8-Arg9, involved in 
several pathophysiological conditions including among others, septic and hemorrhagic shock, anaphylaxis, arthritis, 
rhinitis, asthma, inflammatory bowel disease. Accordingly, BK antagonists have long been sought after for 
therapeutic intervention. Action of BK is mediated through two different G-protein coupled receptors known as B1 
and B2. The former is up-regulated during inflammation episodes or tissue trauma whereas the latter, is 
constitutively expressed in a variety of cell types, mediating most physiological actions of bradykinin [1-3]. Most 
attempts in the past were devoted to develop antagonists of the B2 receptor [4], with a stride made after the 
market release of the peptide antagonist Icatibant [5,6]. More recently, the demonstrated implication of B1 in 
establishing and maintaining the signaling of chronic and inflammatory pain [3,7,8], as well as in hyperalgesia and 
leucocyte infiltration through the activation of a cytokine network, has increased the interest in finding small 
molecule B1 antagonists for the treatment of both pain and inflammation [9-13]. Despite of these efforts there is 
no drug currently in the market designed to antagonize the B1 bradykinin receptor. 
The goal of the present work is to carry out a structure-activity study of B1 antagonism, taking into account 
the stereochemical features of diverse non-peptide antagonists described in the literature and understand how these 
features translate into ligand anchoring points and complementary regions of the receptor, through the analysis of 
the respective ligand-receptor complexes. For this purpose we selected a set of compounds from the literature 
covering the maximal structural diversity as shown in Figure 1. The six compounds selected for the present study 
include Merck compounds 11 (1) [14-16] and 12 (2) [17]; Novartis NPV-SAA164 (3) [18,19]; Amgen Chroman28 (4) 
[20,21]; Sanofi-Synthelabo SSR240612 (5) [22] and Pharmacopeia PS020990 (6) [23]. The selected compounds 
were docked onto a refined model of the BK B1 receptor constructed by homology modeling, following the procedure 
explained in the methods section, being the complexes further analyzed for their ligand-receptor interactions. The 
outcome of this study is summarized on a 3D pharmacophore that explains the observed structure-activity results 
and provides insights into the discovery of novel molecules with antagonistic profile at the B1 bradykinin receptor.  
Methodology 
Computational methods 
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A starting model of the human BK B1 receptor was constructed by homology modeling using the 
chemokine CXCR4 receptor as template (pdb entry code 3ODU) [24]. This template was selected among those 
GPCRs whose crystallographic structure is available based on its proximity to B1 receptor in the GPCRs 
phylogenetic tree. The sequences of the two receptors were aligned, taking into account the conserved motifs 
found in all GPCRs, as well as the location of the disulfide bridges. These motifs, together with salt bridges are 
important factors in constraining the conformation of the extracellular and transmembrane domains of the 
receptor. Sequences were found to share about 25% sequence identity. Additionally, since the chemokine 
CXCR4 lacks the expected helical TM8, residues of the B1 receptor known to be in the TM8, starting from the 
highly conserved NPXXY motif [25] were modeled using the corresponding segment of the crystal structure of 
bovine rhodopsin (pdb entry code 1GZM) [26]. From the aligned sequences and the template backbone, a 
starting model of the receptor was constructed using the Modeller 9 version 8 (9v8) software [27].  Model was 
validated using the Molecular Operating Environment (MOE) program [28] after checking diverse steric 
parameters such as side chain rotamers, inter-residue contacts or backbone conformations. 
In a subsequent step, compound 11 (1 in Figure 1) was docked into the starting model for receptor 
refinement using the GLIDE software [29]. The choice of this ligand was due to the abundant information 
available on receptor residues involved in its binding from site directed mutagenesis experiments [14-15]. Finally, 
the ligand-receptor complex was refined using molecular dynamics of the ligand-receptor complex embedded in 
a lipid bilayer. Specifically, the protein was embedded in a box consisting in 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) lipids and water molecules generated and equilibrated according to the procedure 
described previously [30]. The box had an initial size of 10.3 x 8.0 x 10.2 nm3 (XYZ), organized in such a way 
that the bilayer plane was oriented on the XY plane. Before protein insertion, the box contained 256 lipids 
(corresponding to an area per lipid of 0.64 nm2) and circa 17,000 water molecules. The protein was placed in the 
center of the box, and the overlapping molecules were removed. Specifically, all water molecules with oxygen 
atoms closer than 0.40 nm to a non-hydrogen atom of the protein and similarly, all lipid molecules with at least 
one atom closer than 0.25 nm to a non-hydrogen atom of the protein were removed. This resulted in a final 
system containing 197 lipids and circa 16,000 water molecules. Removal of these atoms introduced small voids 
between the protein and water or lipid molecules that disappeared during the first part of the MD simulation, in 
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which a progressive adjustment of the lipid bilayer and water molecules to the protein takes place. Next, 114 
randomly selected water molecules were replaced by 58 sodium and 56 chloride ions, providing a neutral system 
with a concentration approximately 0.2 M on sodium chloride. This concentration is fairly similar to that found in 
biological organisms, although they exhibit different intra- and extra-cellular ion concentrations. Sampling was 
carried out at 300K for 600ns using GROMACS 4.6 package [31]. The final model of the B1 receptor was 
generated from the average structure of the molecular dynamics trajectory using the last 100 ns. The average 
structure of the receptor was subsequently minimized in a two-step process using the steepest descent method 
with a dielectric constant of 2. First, side chains are optimized with the backbone atoms constrained to be 
subsequently released in a second minimization. This structure was used for further docking studies using the 
GLIDE [29] software. Due to the flexibility of the ligands, the docking process was carried out using a set of 
unique conformations resulted from thorough conformational searches. Poses were rank ordered using the XP 
score function of GLIDE [32]. Final poses of the compounds were decided based on their ranking and fulfillment 
of site directed mutagenesis information available. Final poses were energy minimized using the steepest decent 
method with a dielectric constant of 2, using the OPLS-AA force field [31] to get a full relaxation of the ligand-
receptor complexes. 
Binding assays 
B1 antagonism assays were carried out following a protocol described elsewhere [33]. Specifically, 
compounds were tested on human recombinant bradykinin B1 receptors expressed in CHO cells. Saturation 
isotherms were obtained with [3H] des-Arg10-BK (0.35 nM) incubated for 60 minutes at room temperature. Non-
specific binding was evaluated by adding desArg9[Leu8]-BK at 10 M. Antagonism of unlabeled compounds was 
measured as a percent inhibition of control specific binding of [3H]-bradykinin obtained in the presence of the test 
compounds at one concentration using NPC-567 as reference compound. 
Results and discussion 
Construction and refinement of the 3D model of the B1 receptor 
In the absence of a crystallographic structure of the B1 receptor, we proceeded to construct an atomistic 
model using homology modelling. Although the number of crystallographic structures of GPCRs available has 
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increased steadily during the last few years, there are still challenges that hinder the availability of new ones, 
including their low-expression yields, low receptor stability after detergent extraction from native membranes, and 
high conformational heterogeneity. Under these circumstances homology modelling remains one of the important 
techniques aimed at constructing 3D models of proteins, however in order for the models constructed to be as 
accurate as possible the procedure requires a careful choice of the template and a robust refinement procedure 
[34-36]. This consideration is important since the analysis of the diverse crystallographic structures reveals that 
although they all share a common seven helix bundle, each structure exhibits specific features that might be 
relevant for ligand design [37].  
Figure 2 shows the alignment of the sequences of the CXCR4 and B1 receptors carried out taking into 
account the conserved motifs found among GPCRs, as explained in the methods section. This procedure is 
crucial for the assignment of the transmembrane regions. The N-terminus of the B1 receptor as well as 
transmembrane regions TM1-TM6 and part in TM7 were constructed using CXCR4 chemokine receptor as a 
template (pdb entry code 3ODU) [24], while the part in TM7 starting from the conserved motif NPXXY was 
constructed using bovine rhodopsin as a template (pdb entry code 1GZM) [26]. This information was used as 
input of the Modeller software that produced a set of models that were subsequently rank ordered based on a 
scoring function. The final model selected for the refinement process was the one with the least steric conflicts 
from those that incorporated all the specified constraints considered to be conserved among GPCRs. 
As mentioned before, structure refinement was carried out through a molecular dynamics simulation of 
the receptor embedded in a lipid bilayer. Previous experience on GPCR homology modeling, suggests that the 
presence of the ligand permits a faster equilibration of the system (data not shown). In this case compound 11 
(compound 1 in Figure 1) was docked into the orthosteric site in the starting model. The orthosteric site of the B1 
receptor is shown in the context of the B1 receptor in Figure 3. It can be described as a large highly hydrophobic 
pocket formed by TM2, ECL1 and TM7 including residues Trp-932.60, Ile-972.64, Phe-101ECL1, Phe-2997.40, Phe-
3027.43 on one side of the binding pocket. Interestingly, interactions at this side of the pocket involving Trp-932.60, 
Phe-101ECL1 and Phe-2997.40 are quadrupole-quadrupole interactions. (The Ballesteros-Weinstein notation is 
used for clarity [38].) On the other side of the binding pocket both polar and hydrophobic residues such as, Asn-
1143.27, Arg-2025.38 and Tyr-2666.51 can be identified. Finally, at the top and mouth of the binding site there are 
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several polar residues including Glu-1965.32, His-1995.35, Glu-2736.58, Gln-2776.62, Glu-2877.28, Asp-2887.29, Asp-
2917.32.   
Several docking attempts were carried out using diverse conformations that had been generated 
automatically as explained in the methods section. The final complex considered for refinement was selected 
based on the degree of fulfilment of the available site directed mutagenesis studies published in the literature. In 
a subsequent step, the B1 receptor–compound 11 complex was embedded into a box of a pre-equilibrated 
bilayer of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and water and subject to molecular 
dynamics simulations. The time evolution of the root mean square deviation (rmsd) of the alpha carbons of the 
whole protein as well as those of the helical bundle subset (data not shown) indicates that equilibration is 
reached after 300 ns when all the alpha carbons of the protein are considered, whereas equilibration is reached 
about 50 ns earlier when the helical bundle subset is used in the calculation.  
The refined model of the BK B1 receptor was produced from the average structure of the last 100 ns of 
the molecular dynamics trajectory. Since the receptor structure is expected to exhibit small structural variations 
around the starting point during the refinement process, we consider that an average structure picks up 
information of the diverse structures sampled. Moreover, crystallographic structures are average structures in 
nature. The average structure was subsequently minimized in a two-step process using the steepest descent 
method with a dielectric constant of 2. First, side chains are optimized with the backbone atoms constrained to 
be subsequently released in a second minimization. This process was aimed to relax the structure to the nearest 
minimum in a practical manner, avoiding the minimizer spend most of the minimization process reorienting 
solvent molecules. 
This structure was used for the docking study of the different ligands selected in the present study. Below, 
we describe the proposed bound conformation of each of the diverse antagonists from the corresponding 
docking studies on the refined model.  
Docking studies of the diverse antagonists selected 
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Compound 11 
Compound 11 (1 in Figure 1) was discovered at Merck in the optimization process of a 
dihydroquinoxalinone lead previously identified as BK B1 receptor antagonist in an in-house screening process 
[14]. Compound 11 antagonizes both des-Arg9-BK and Lys-des-Arg9-BK induced contraction of the rabbit 
isolated aorta [13], exhibiting a notable binding affinity for the BK B1 receptor in diverse animal species. Thus, in 
humans its Ki is 0.034 nM [16]. Mutagenesis studies show that mutation of residues Ile-972.64, Trp-98ECL1, Asn-
1143.27, Gln-2957.36, Asp-2917.32 and Glu-2736.58 affect the binding affinity in various degrees, while mutation of 
Asn-2987.39 exhibits little impact on the binding affinity to the BK B1 receptor [15]. On the other hand, structure-
activity studies suggest that the imidazole group is crucial for the high affinity of the compound, since its affinity is 
drastically reduced when it is substituted for a hydrophobic moiety [15]. Similarly, elimination of the fused 
aromatic ring of the dihydroquinoxalinone moiety reduces its affinity one order of magnitude. Finally, substitution 
of the sulfone by a carbonyl group reduces affinity one order of magnitude. In contrast, substitution of the 
dichlorophenyl moiety by a naphthyl group retains affinity. 
As can be seen in Figure 4, the proposed bound conformation of compound 11 shows the 
dihydroimidazole group seating in a polar region surrounded by residues His-1995.35, Glu-2736.58 and Asp-2917.32. 
This explains the observed affinity boost produced by the addition of this moiety to the ligand [14]. The nitrogen 
and carbonyl groups of the dihydroquinoxalinone moiety exhibit hydrogen bonds with the sidechains of Asn-
1143.27 and Arg-1764.64, whereas the fused benzene ring exhibits as T-shaped aromatic ring-aromatic ring 
interaction with Tyr-2666.51. Loss of the hydrogen bond interaction of the Asn-1143.27 explains the reduction of an 
order of magnitude in affinity observed in the Asn144Ala mutant [15] or in the less detrimental mutation to Ser also 
found in the rat B1 BK receptor [15, 16]. A hydrogen bond is observed between thionyl oxygen of the 
sulfonamide shared between Gln-2957.36 and Asn-2987.39. Actually, mutagenesis experiments show that mutation 
of Gln-2957.36 to alanine reduces the binding affinity of compound 11 more than one order of magnitude [15]. The 
other thionyl oxygen is likely involved in a intramolecular hydrogen bond with the amide group. The 
dichlorophenyl moiety is located in a hydrophobic pocket conformed by Trp-932.60, Ile-972.64, Trp-98ECL1 and Phe-
101ECL1 and Phe-2997.40. Mutagenesis analysis supports the importance of Trp-98ECL1 in the affinity of the 
compound [15]. The proposed bound conformation described above is in agreement with aforementioned SAR 
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and mutagenesis studies and complements further the homology model of BK B1 carried out previously using 
rhodopsin as template [14, 15]. Despite the two models coincide in the description of the bound conformation of 
compound 11, present model provides additional information about the role of diverse residues like Gln-2957.36 as 
responsible for the thionyl interaction; Asn-1143.27 and Arg-1764.64 as well as Tyr-2666.51 as responsible for the 
interaction with the dihydroquinoxalinone moiety; the involvement of Trp-932.60 in the interaction with the 
dichlorophenyl moiety and the involvement of His-1995.35 in the interaction with the phenyl group, as well as the 
hydrogen bond between the carbonyl of the central amide group and the side chain of Arg-2025.38. 
Compound 12 
The proposed bound conformation of compound 12 (2 in Figure 1) to the BK B1 receptor is shown in 
Figure 5. The molecule exhibits its 4-pyridinylpiperazinyl group interacting with several residues at the mouth of 
the binding pocket. Specifically, one of the nitrogens of the 4-pyridnyl moiety exhibits a hydrogen bond with the 
side chain of Asp-2917.32, while the pyridine ring interacts with Phe-2766.61. Support to the existence of an 
aromatic ring-aromatic ring interaction is given by the reduction of affinity observed in rats (from a Ki of 0.59 in 
human to 0.92 in rat), since in rat Phe-2766.61 is mutated to Val [17]. The smaller affinity observed can be 
explained to be due to the absence of the more preferred quadruple–quadruple interaction than the hydrophobic 
interaction. Moreover, the bridging phenyl group attached to the piperazinyl ring forms a - stacking with His-
1995.35. In the central section of the molecule the carbonyl group of the substituted urea exhibits a hydrogen bond 
interaction with Gln-2957.36 as well as the carbonyl of the diazepine ring does with Arg-2025.38. Aromatic residues 
at the bottom left of the binding pocket (Trp-932.60 and Phe-2997.40) form a π-π stacking with the fused benzene 
ring, while the phenexyl moiety interacts with both the Trp-932.60 and the Phe-101ECL1.  
Despite the lack of mutagenesis studies on this ligand that permit to corroborate the proposed bound 
conformation of compound 12, there is a limited SAR available that can be used to support present results [17]. 
Thus, the importance of a proton accepting center interacting with Asp-2917.32 is supported by the fact that 
elimination of the peperidine nitrogen that has attached the 4-pyridinyl group reduces drastically the affinity of the 
new analog, although it is recovered in part when the pyridinyl ring is replaced by a piperazine ring. It is intriguing 
though that substitution of the 4-pyridinyl ring by a phenyl group produces a non-binder. Our docking results 
predict a similar role for any of the two aromatic rings: a quadrupole-quadrupole interaction with Phe-2766.61 with 
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no specific role for the pyridinyl nitrogen, but increasing the solubility of the compound. Accordingly, we suggest 
as an alternative explanation that the lack of affinity observed is due to the small expected solubility of the 
compound.  
Finally, diverse substitutions at the core benzodiazepine C-5 position show that short alkyl groups 
decreased affinity. In contrast, the introduction of a cyclohexyl group increased substantially affinity and 
furthermore, the substitution of a phenethyl group enhanced affinity by 4-fold at the human BK B1 receptor. This 
supports present results, since Trp-932.60 and Phe-101ECL1 are far from the benzodiazepine ring. 
NPV-SAA164 
Developed by Novartis, NPV-SAA164 is an antihyperalgesic orally bioavailable B1 antagonist with Ki of 8 
nM in HEK293 cells expressing human B1 receptor and no activity in rat B1 receptor [18,19]. The compound was 
discovered through an in-house screening of a set of non-peptide B2 antagonists that had been previously 
described [39].  An extensive medicinal chemistry work led to the discovery of NPV-SAA164 (3 in Figure 1) from 
a set of diverse analogs based on a 2-alkylamino-5-sulfamoylbenzamide core. 
Figure 6 shows the proposed bound conformation of NPV-SAA164 to the BK B1 receptor. The proposed 
bound conformation shows the methylpiperazine group located at the mouth of the binding pocket exhibiting a 
hydrogen bond with the side chain of Asp-2917.32. Further down, the piperidine moiety although hypothesized to 
act as spacer, is positioned in such a way that interacts with the aromatic imidazole ring of His-1995.35. Further 
down along the structure, the morpholine group sits in a polar region surrounded by Arg-2025.38, Tyr-2666.51 and 
Asn-2987.39 with a hydrogen bond interaction between the oxygen of the ring and Arg-2025.38 and the carbonyl 
group linking the morpholine and amino moiety attached to the phenylsulfonamide group interacts with Gln-
2957.36 side chain via a hydrogen bond. The phenylsulfonamide group also interacts with both the backbone of 
Leu-191ECL2 via hydrogen bond with the sulfonyl-oxygen and the sidechain of Leu-193ECL2 through a van der 
Waals interaction. SAR studies show that the presence of an amide group increases affinity suggesting the 
ability to form a hydrogen bond [18]. Finally, the hydrophobic 2,2-diphenylethanamine group at the terminus of 
the ligand sits in the aromatic pocket of our B1 receptor model, in such a way that interacts with both the Trp-
932.60 at the bottom of the aromatic pocket in TM2 and Trp-98ECL1 and Phe-101ECL1, at the top of the aromatic 
pocket. 
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Chroman 28 
Chroman-28 developed by Amgen, is a potent and selective antagonist of human, non-human primate, 
rat, and rabbit bradykinin B1 receptors with anti-inflammatory activity and Ki between 0.7 nM at human B1 
receptors [20]. Chroman 28 was developed from extensive medicinal chemistry studies devoted to optimize the 
spatial placement of a lipophilic sulfonamide and a basic amine moiety, previously noted to be important for high 
binding affinity to the B1 receptor [40].  
Figure 7 shows the proposed bound conformation of Chroman 28 to the human B1 receptor. Analysis of 
the ligand-receptor interactions starting from the piperidine ring reveals that this moiety sits in a negatively 
charged region at the mouth of the receptor displaying a hydrogen bond interaction with the sidechain of Asp-
297.32. SAR studies reveal that the piperidine ring can be replaced by diverse amines, being the pyrrolidine or 
butylamine the most active analogs. In contrast, replacement by a hydroxyl group leads to a complete loss of the 
affinity [41]. These results support the positioning of the piperidine ring described in the present model, since an 
amine can interact adequately with the diverse acid residues of the region including Asp-2917.32, Glu-2736.58 or 
Glu-2877.28. Replacement of an amine by a hydroxyl group generates a phenol derivative that at neutral pH will 
be in its basic form. This results agree well with the proposed pharmacophoric requirement for B1 antagonism 
mentioned above [40].Further down the molecule, the chroman group is located close to the side chain of His-
1995.35 interacting through a hydrogen bond between the oxygen of the chroman moiety and one of the nitrogens 
of the imidazole group and, also through a quadrupole-quadrupole interaction between the two rings. The model 
clearly justifies the differential affinity observed between the R and S enantiomers in SAR studies [41]. Further 
down the molecule, the amide carbonyl group exhibits a hydrogen bond with the side chain of Arg-2025.38 and 
one of the sulfonyl oxygens with the side chain of residue Gln-2957.36. Interestingly, the other sulfonyl oxygen 
interacts with Arg-1764.64 located at the C-terminus of TM4 via a hydrogen bond. Moreover, the phenyl group of 
the aryl sulfonamide core interacts with Tyr-2666.51, albeit at a bit longer distance. Improvement of this interaction 
led to the discovery of a sulfonamide containing a 2-oxopiperazine [42]. Finally, the naphthalene group sits in the 
aromatic pocket where quadruple-quadruple interactions with Trp-932.60, as well as Phe-101ECL1 are formed. SAR 
studies show that this moiety can be replaced by a trifluorobenzene without affinity loss, supporting the 
environment where the naphtyl group is located in the present model [42]. 
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SSR240612 
SSR240612 is a high affinity antagonist of Lys-des-Arg9 in HEK cells expressing human B1 receptor and 
MRC5 human lung fibroblast B1 expressing cells. Developed by Sanofi, SSR240612 was the first B1 receptor 
antagonist with proven efficacy and oral bioavailability in models of pain and inflammation [22, 43].  
The proposed bound conformation of SSR240612 to the BK B1 receptor is shown in Figure 8. Similarly as 
found in Chroman 28, the nitrogen of the piperidine moiety exhibits a hydrogen bond with Asp-2917.32. Further 
down the molecule the isopropylamide group sits in a region with several hydrophobic residues including Leu-
191ECL2 and Leu-193ECL2. In the center of the molecule, the amide group exhibits a hydrogen bond with Gln-
2957.36. Close to it the sulfonamide group exhibits a hydrogen bond between one of the thionyl groups and the 
side chain of residues Arg-1764.64, whereas the other exhibits a hydrogen bond with the amide hydrogen of Leu-
191ECL2 backbone. Attached to the sulfonamide there is a benzodioxole moiety that sits in a region with several 
aromatic residues including Trp-932.60 and Phe-101ECL1. On the other side of the molecule, the oxygen of the 
diaxole moiety interacts with Asn-96ECL1 via hydrogen bond. Finally, the methoxynaphthyl group interacts with 
residue Tyr-2666.51and Asn-2987.39. 
PS020990 
Discovered by Pharmacopeia from a throughput screening program using encoded combinatorial 
libraries, PS020990 exhibits a potent antagonist profile on human BK B1, inhibiting 3H-Des-Arg10-Kalidin at IMR-
90 cells with a K1 of 1nM [23]. PS020990 is a high selective BK B1 antagonist with a >1000-fold selectivity 
reported over B2R [23].  
The proposed bound conformation of PS020990 is shown in Figure 9. Present docking studies reveal 
the imidazole ring sitting at the polar top end of the binding pocket interacting with the His-1995.35 and exhibits a 
hydrogen bond with Glu-2736.58. Next to the imidazole group there is a pyridine ring that acts as spacer. It has 
attached a 3-chlorobenzylamine moiety that exhibits two hydrogen bond interactions, including the amine 
nitrogen with Arg-2025.38 and the chlorine of the 3-chlorobenzyl moiety with the sidechain of Asn-1143.27. Further 
down the molecule, the carbonyl oxygen of the central amide exhibits a hydrogen bond with Gln-2957.36, while the 
propylcyclohexane moiety sits close to Ile-190ECL2. At the terminal end of the molecule the 4-chlorobenzyl group 
rests at the center of the aromatic site, coordinating the π-π interactions with Trp-932.60 that also involves Phe-
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2997.40.  
 
Definition of a pharmacophore for recognition to the bradykinin B1 receptor  
Comparison of the ligand-receptor complexes of the diverse antagonists used for the present study 
allows the definition of a pharmacophore that explains the observed structure-activity relationship observed. To 
define a pharmacophore of the ligand-receptor interaction, we superimposed the proposed bound structures as 
found in the ligand-receptor complex resulted from molecular docking studies. Analysis of the superimposed 
structures permitted the identification of common chemical features in similar regions of the space namely, the 
pharmacophoric points. For each of these pharmacophoric points an average geometric center was computed 
using the atomic centers of the participating atoms among the diverse antagonists. No exclusion volumes were 
incorporated in the pharmacophore, although the virtual screening procedure included a docking process after 
searching hits for pharmacophore fulfilment in order to eliminate the molecules that crashed with the receptor. 
The proposed pharmacophore is shown in Figure 10. It consists of five pharmacophoric points that all the ligands 
studied in the present study fulfil. The first point, at the polar mouth of the binding pocket, is represented by a 
proton donor center that complements an interaction with Asp-2917.32 and/or Glu-2736.58 and His-1995.35; point 2 is 
either a proton donor/proton acceptor center that will interact with either Gln-2957.36; point 3 is a hydrophobic ring 
that will interact with Trp-932.60 and/or Phe-2997.40; point 4 is a proton accepting center that will interact with Asn-
1143.27 and/or Arg-1764.64; point 5 is a proton donor and /or proton acceptor site that will interact with Arg-2025.38, 
Asn-2987.39 and the side chain of Tyr-2666.51. 
 All the compounds used for pharmacophore development (Figure 1) fulfil all five receptor points. It what 
follows we specify how specific moieties of the diverse compounds fulfil the pharmacohpric hypothesis. Thus, 
Compound 11 fulfils point 1 by means of the 2-phenyldihydroimidazole; point 2 by the sulfonamide oxygen; point 
3 by means of the chlorophenyl moiety; point 4 by the oxygen of the dihydroquinoxalinone group and point 5 by 
means of by the oxygen of the amide linker group. For Compound 12, point 1 is fulfilled by the 4-
pyridinepiperazine moiety; point 2 is fulfilled by means of the amide linker moiety; point 4 by both the cyclohexyl 
group and the benzyl moiety of the benzodiazepine and point 4 and 5 are fulfilled by the carbonyl group of the 
diazepine moiety. In the case of the NPV-SAA164 point 1 is fulfilled by the methyl-piperazine group nitrogen; 
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point 2 by means of the carbonyl group linking to the morpholine group that fulfills point 4; point 3 by both the 
phenyl group providing maximum coverage of the pocket side, point 5 by means of the sulfonyl oxygens of the 
sulfonamide. Chroman-28 covers the pharmacophore point 1 by using the chroman-7-methylpiperidine, point 2 
and point 4 by means of the oxygens of the sulfonamide group; point 3 is fulfilled by the naphthalene rings and 
point 5 by the linker amide carbonyl group. In SSR240612 point 1 is fulfilled by the dimethyl-piperidine group; 
point 2 is fulfilled by the carbonyl group of the amide linker; point 3 is fulfilled by the benzodioxole moiety; while 
the sulphonyl oxygen fulfils point 4 and point 5 is fulfilled by the methyl-propanamide group. Finally, in the case 
of compound PS020990 point 1 is fulfilled by the imidazole group; point 2 by the carbonyl group of the cyclohexyl 
propanamide moiety; point 3 by means of the chlorophenyl group adjacent to the cyclohexyl propanamide moiety 
and point 5 by means of the nitrogen of the pyrimidine ring. 
 
Proof of concept 
The pharmacophore described above was later used in the discovery of novel structures with 
antagonistic activity for BK B1 by virtual screening. For this purpose a search was made in few databases of 3D 
structures of compounds including the Available Chemical Directory (ACD), the Derwent World Drug Index, the 
National Cancer Institute (NCI) and Maybridge for approximately 500,000 compounds. A separated searches for 
compounds fulfilling five, four and three pharmacophoric points yielding a large set of compounds was carried 
out. A selected group of them were purchased and tested for their BK B1 antagonistic activity.  
Biological assays permitted to identify new highly diverse hits with structures that do not resemble those 
used for pharmacophore development. The success rate achieved to identify new hits with an antagonistic 
activity by virtual screening was approximately one third of the selected molecules, as previously found by other 
authors [44]. Table 1 shows the structures as well as the antagonistic activity to the human bradykinin BK B1 of a 
selected group of hits that are disclosed to give support to the pharmacophoric hypothesis developed in this 
work. These molecules were docked onto the receptor model and inspected for fulfilment of the pharmacophore. 
Information regarding the number of pharmacophoric points fulfilled by each of the hits is also included in Table 
1. Interestingly, the antagonistic activity observed experimentally correlates well with the number of 
pharmacophoric points fulfilled by these molecules. 
As an example, Figure 11 shows compound #10 bound to the BK B1 showing the fulfilment of the 
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pharmacophoric points. The ligand is shown to fulfil 3 pharmacophoric points 1, 3 and 5.  The charged amine 
moiety interacts with the Asp-2917.32, and thus fulfilling point 1, the indole group nest deep in the hydrophobic 
pocket and fulfils point 3 and finally the nitrile group fulfils point 5 by interacting via hydrogen bond with both the 
sidechain of Tyr-2666.51 and Arg-2025.38. While the molecule have other polar groups such as carbonyl that could 
interact with Gln-2957.36 and Asn-1143.27, the size and conformation of these moieties and the compound in 
general, are not adequate enough to orient in a suitable manner for proper interactions. This emphasizes the 
reason why most of the BK B1 antagonists published are big as they need to span out to all pharmacophoric 
points to suitably interact. 
Conclusions 
Models of the bound conformation of diverse non-peptide human BK B1 antagonists were constructed and 
the stereochemical features of the complexes were analyzed with the aim to find common trends. To accomplish 
this, an atomistic model of the receptor was constructed by homology modeling, using the human CXC4 
chemokine and bovine rhodopsin receptor as template (chimeric template). Antagonists selected for the present 
study included Compound 11, Compound 12, NPV-SAA164, Chroman-28, SSR240612 and PS020990, covering 
the maximum possible diversity. Complexes with the bound conformation of each of the antagonists were 
constructed by docking the molecules into the receptor. Due to the flexibility of the ligands and the size of the 
orthosteric site of the receptor, several docking attempts were carried out for each of the molecules. The final 
conformation was selected by the scoring function and the results of both SAR and site directed mutagenesis 
studies available in the published literature. 
Our results suggest that there are certain anchoring points that are found in more than one compound 
permitting the definition of a common pharmacophore. This consist of five points that defined on the features of 
the ligand include proton donor (point 1); a proton acceptor/proton donor center (point 2); a hydrophobic ring 
(point 3); proton acceptor/proton donor center (point 4) and proton donor/proton acceptor. 
The pharmacophore was used in a subsequent study to guide a virtual screening process. The results 
permitted to identify a set of compounds some of which were purchased and in vitro tested for their capability to 
antagonize the BK B1. Consequently, a subset of compounds with highly diverse structures that give support to the 
validity of the pharmacophoric hypothesis described in this work was also disclosed.  
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Captions to the Figures 
Figure 1: Chemical structures of the B1 antagonists studied in the present work. Compound 11 (1), Compound 
12 (2), NPV-SAA164 (3), Chroman28 (4), SSR240612 (5) and PS020990 (6). 
Figure 2: Sequence alignment of human B1 receptor (bottom) with human CXC4 chemokine receptor and 
bovine receptors (for part in TM7 and TM8). Transmembrane segments are inserted in boxes colored in green. 
Figure 3: (a) Lateral view of the orthosteric binding pocket of the human B1 bradykinin receptor modeled in 
complex with compound 11, ( b) same as (a) viewed from the extracellular side (aerial). 
Figure 4. Pictorial view of the proposed binding mode of Compound 11 bound to the BK B1 receptor. 
Figure 5: Pictorial view of the proposed binding mode of Compound 12 bound to the BK B1 receptor. 
Figure 6: Pictorial view of the proposed binding mode of NPV-SAA164 bound to the BK B1 receptor. 
Figure 7: Pictorial view of the proposed binding mode of Chroman 28 bound to the BK B1 receptor. 
Figure 8: Pictorial view of the proposed binding mode of SSR240612 bound to the BK B1 receptor. 
Figure 9: Pictorial view of the proposed binding mode of PS020990 bound to the BK B1 receptor. 
Figure 10: Proposed pharmacophore for the BK B1 antagonism. Distance between pharmacophoric points are: 
d(1,2)= 9.2 A; d(1,3)=13.1; d(1,4)= 1.5; d(1,5)=9.5; d(2,3)=5.1; d(2,4)=7.6.; d(2,5)=9.3; d(3,4)=7.8; d(3,5)=9.5; 
d(4,5)=5.7 
Figure 11: Pictorial view of compound #9 of Table 4.2 bound to the BK B1 receptor with the pharmacophore 
points represented as spheres of different colors. 
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Table 1. Structures of the new hits discovered together with their antagonistic effect towards the human BK B1 receptor and 
the number of pharmacophore points fulfilled. 
 
 
